In addition, it would also be interesting to investigate the other promoters, especially those described to be mostly breast cancer tissue-specific, such as ErbB2 and MUC1, or a BCSC-specific promoter, like MDR, to further enhance the therapeutic potential of OAd expressing hNIS. Here, MUC1 is linked to breast carcinoma.